Partial renal remission · patients with induction therapy in lupus nephritis
Mycophenolate mofetil (MMF) showed no clear difference in partial renal remission compared with IV cyclophosphamide (CPA) (low certainty).
1 finding from 1 review
Ovarian failure · patients with induction therapy in lupus nephritis
It is very uncertain whether mycophenolate mofetil (MMF) changes ovarian failure compared with IV cyclophosphamide (CPA) (very low certainty).
1 finding from 1 review
Major infection · patients with induction therapy in lupus nephritis
Mycophenolate mofetil (MMF) showed no clear difference in major infection compared with IV cyclophosphamide (CPA) (low certainty).
1 finding from 1 review
Alopecia · patients with induction therapy in lupus nephritis
Mycophenolate mofetil (MMF) probably leads to lower alopecia compared with IV cyclophosphamide (CPA) (moderate certainty).
1 finding from 1 review
Diarrhoea · patients with induction therapy in lupus nephritis
Mycophenolate mofetil (MMF) probably leads to higher diarrhoea compared with IV cyclophosphamide (CPA) (moderate certainty).
1 finding from 1 review
All‐cause mortality · adults with primary (essential) hypertension whose systolic or diastolic (or both) blood pressure levels were 130/80 mmHg or greater
It is very uncertain whether evening changes all‐cause mortality compared with morning dosing regimen (very low certainty).
1 finding from 1 review
Cardiovascular mortality · adults with primary (essential) hypertension whose systolic or diastolic (or both) blood pressure levels were 130/80 mmHg or greater
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Cardiovascular morbidity · adults with primary (essential) hypertension whose systolic or diastolic (or both) blood pressure levels were 130/80 mmHg or greater
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · adults with primary (essential) hypertension whose systolic or diastolic (or both) blood pressure levels were 130/80 mmHg or greater
It is very uncertain whether evening changes serious adverse events compared with morning dosing regimen (very low certainty).
1 finding from 1 review
Overall adverse events · adults with primary (essential) hypertension whose systolic or diastolic (or both) blood pressure levels were 130/80 mmHg or greater
It is very uncertain whether evening changes overall adverse events compared with morning dosing regimen (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · adults with primary (essential) hypertension whose systolic or diastolic (or both) blood pressure levels were 130/80 mmHg or greater
It is very uncertain whether evening changes withdrawals from treatment due to adverse events compared with morning dosing regimen (very low certainty).
1 finding from 1 review
Non‐infectious complications · people undergoing gastrointestinal surgery
It is very uncertain whether preoperative parenteral nutrition changes non‐infectious complications compared with usual care or control (very low certainty).
1 finding from 1 review
Infectious complications · people undergoing gastrointestinal surgery
Immune‐enhancing supplements (oral or enteral) showed no clear difference in infectious complications recorded up to 30 days postdischarge compared with usual care or control (low certainty).
1 finding from 1 review
Length of hospital stay · people undergoing gastrointestinal surgery
1 finding from 1 review
Adverse effects · people undergoing gastrointestinal surgery
1 finding from 1 review
Non‐infectious complications · people undergoing gastrointestinal surgery
Oral nutritional supplements showed no clear difference in non‐infectious complications recorded up to 30 days postdischarge compared with usual care or control (low certainty).
1 finding from 1 review
Infectious complications · people undergoing gastrointestinal surgery
It is very uncertain whether oral nutritional supplements changes infectious complications recorded up to 30 days postdischarge compared with usual care or control (very low certainty).
1 finding from 1 review
Length of hospital stay · people undergoing gastrointestinal surgery
1 finding from 1 review
Adverse effects · people undergoing gastrointestinal surgery
1 finding from 1 review
Infectious complications · people undergoing gastrointestinal surgery
It is very uncertain whether preoperative parenteral nutrition changes infectious complications compared with usual care or control (very low certainty).
1 finding from 1 review